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Mutations inCOCH (coagulation factor C homology) are etiologic for the late-onset, progressive, sensorineural
hearing loss and vestibular dysfunction known as DFNA9.We introduced the G88Emutation by gene targeting
into themouseandhavecreatedaCochG88E/G88Emousemodel for thestudyofDFNA9pathogenesisandcochlin
function. Vestibular-evoked potential (VsEP) thresholds of CochG88E/G88Emice were elevated at all ages tested
comparedwithwild-type littermates. At the oldest ages, two out of eightCochG88E/G88Emice had nomeasurable
VsEP. Auditory brainstem response (ABR) thresholds of CochG88E/G88Emice were substantially elevated at 21
months but not at younger ages tested. At 21 months, four of eight CochG88E/G88E mice had absent ABRs at
all frequencies tested and two of three CochG88E/1mice had absent ABRs at three of four frequencies tested.
Distortion product otoacoustic emission amplitudes of CochG88E/G88E mice were substantially lower than
Coch1/1 mice and absent in the same CochG88E/G88Emice with absent ABRs. These results suggest that vesti-
bular function is affected beginning as early as 11 months when cochlear function appears to be normal, and
dysfunction increases with age. Hearing loss declines substantially at 21 months of age and progresses to
profound hearing loss at some to all frequencies tested. This is the only mouse model developed to date
where hearing loss begins at such an advanced age, providing an opportunity to study both progressive
age-related hearing loss and possible interventional therapies.
INTRODUCTION
COCH (coagulation factor C homology) and its encoded
protein, cochlin, are expressed at high levels in the inner ear
as initially shown by northern blot, tissue in situ hybridization,
and immunohistochemistry (1,2). Cochlin is detected by pro-
teomic analysis as the most abundant protein in the bovine
(3), as well as mouse and human inner ears (4). A growing
number of mutations in COCH, causing late-onset, progressive
hearing loss and vestibular dysfunction characteristic of
DFNA9 are being diagnosed (Fig. 1 and Table 1). In addition
to the original mutations clustered in the FCH(factor C homo-
logy)/LCCL(limulus factor C, cochlin, lung gestational
protein) domain (5–8), there are now three mutations reported
in the vWFA2 domain (von Willebrand factor A-like domain)
(9,10), as well as another recently reported mutation (in the
FCH/LCCL domain) in a Dutch kindred (11).
Prevalence of COCH mutations is not known, as there is no
systematic genetic screening worldwide in individuals with
late-onset hearing loss. However, the finding of COCH
mutations on four continents (Table 1), and the observation
of four distinct mutations in the Netherlands alone, suggests
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that the true prevalence of COCH mutations may be substan-
tially higher than currently recognized. In addition, the possi-
bility of COCH playing important roles in presbycusis and
disorders of imbalance has been considered (6,7), and
cochlin has also been shown as a major target antigen for auto-
immune sensorineural hearing loss by both antibody and
T-cell-mediated mechanisms (12–14).
Temporal bones from individuals with DFNA9 exhibit an
intriguing and characteristic histopathology. The number of
fibrocytes in the spiral ligament and in the spiral limbus is
reduced and a homogeneous eosinophilic material is present
in these structures that stain with anti-cochlin antibodies (4).
The relationship between the finding of cochlin-staining eosi-
nophilic material and lack of cellularity remains to be eluci-
dated. In an effort to understand the function of COCH in
the inner ear and its role in pathogenesis of DFNA9 hearing
and balance disorder, we created a mouse knock-in model
designated CochG88E/G88E. Because all mutations known to
date in COCH are either missense or an in-frame deletion,
and none lead to premature termination and truncation of the
protein, we chose to create the targeted missense mutation in
the mouse rather than a null mutant.
The G88E mutation was initially found in a US family (5)
and subsequently in the Netherlands with likely different foun-
ders (15). In vitro studies of the FCH/LCCL domain of bac-
terially expressed cochlin with the G88E mutation (as well
as several others of the mutations) have revealed misfolding
of this domain by nuclear magnetic resonance (NMR) struc-
tural analyses (16). Herein, we report the generation of a
mouse model bearing the G88E mutation, and describe the
results of functional hearing and vestibular testing as well as
histological findings. With age-related hearing loss being the
most common sensory problem in humans, our mouse model
provides potentially an excellent system for its study; this is
the only model to date with onset of hearing loss at this
advanced age.
RESULTS AND DISCUSSION
Verification of the CochG88E/G88E mouse model
RT–PCR analysis. To confirm successful transcription of
mutant Coch, we performed reverse transcription polymerase
chain reaction (RT–PCR) of ribonucleic acid (RNA) isolated
from a CochG88E/þ mouse. An expected product of 1.7 kb
representing the full-length coding region of Coch was
obtained. Sequencing of the PCR product was performed,
showing presence of the introduced Coch mutation as well
as correct splicing of introns 4–6, confirming that the remain-
ing loxP site in intron 5 after deletion of neo (neomycin) does
not disrupt accurate splicing.
Immunohistochemistry. To confirm translation of the mutant
CochG88E/G88E transcript, we performed immunohistoche-
mistry on cochlear and vestibular sections from a 3-month-old
CochG88E/G88E mouse, using an anti-cochlin antibody, which
showed intense and specific cochlin staining in the structures
where cochlin expression is normally seen in the wild-type
inner ear (4) (Fig. 2). Specifically, cochlin immunostaining was
prominent throughout the spiral ligament and spiral limbus in
the cochlea and in the area of stromal fibrocytes in the crista
ampullaris of a semi-circular canal. All immunostaining
Figure 1. Schematic representation of the deduced amino acid structure of human COCH, encoding the protein cochlin, shows a predicted signal peptide (SP),
followed by a domain initially designated as FCH, also known as the LCCL domain, followed by an intervening domain, and two domains (vWFA1 and vWFA2)
separated by an intervening domain. Twelve mutations (all missense except for one in-frame deletion), causing DFNA9 deafness and vestibular disorder, are
indicated. The positions of all cysteine residues are shown as ‘C’.
Table 1. COCH mutations in DFNA9
Origin Exon with mutation Nucleotide change Amino acid change Protein domain Reference
Belgium and The Netherlands 4 C207T P51S FCH/LCCL (6,7)
United States 4 T253G V66G FCH/LCCL (5)
The Netherlands 5 G315T G87W FCH/LCCL (28)
United States and The Netherlands 5 G319A G88E FCH/LCCL (5,15)
Hungary 5 366_368delGTA V104del FCH/LCCL (29)
The Netherlands 5 T382C I109T FCH/LCCL (11)
Australia 5 T382A I109 N FCH/LCCL (8)
United States 5 T405C W117R FCH/LCCL (5)
Japan 5 G411A A119T FCH/LCCL (30)
China 12 T1591C M512T vWFA2 (10)
United States 12 G1681T C542F vWFA2 (9)
China 12 G1681A C542Y vWFA2 (10)
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represents mutant cochlin, confirming successful translation of
the mutant cochlin protein. Of note, inner ear sections from
Coch2/2 immunostained with the same antibody show com-
plete lack of staining (4).
Functional studies: VsEP, ABR and DPOAE
measurements
Vestibular-evoked potential (VsEP) measurements are a
reflection of vestibular function, more specifically of gravity
receptor or otolithic organs, the saccule and utricle. VsEP
thresholds for CochG88E/G88E, CochG88E/þ and Cochþ/þ mice
were obtained at five ages spanning 11–21 months (Fig. 3).
VsEP thresholds of CochG88E/G88E mice were elevated at all
ages tested compared with the Cochþ/þ littermates. At 19
and 21 months, two of the CochG88E/G88E mice had no measur-
able VsEP. VsEP thresholds for CochG88E/G88E and Cochþ/þ
mice at 11, 17, 19 and 21 months were analyzed using a two-
factor analysis of variance (ANOVA, Age X Genotype). The
two factor ANOVA revealed no significant interaction;
however significant main effects were seen for age
[F(3,35) ¼ 4.349, P ¼ 0.01] and genotype [F(1,35) ¼ 15.749,
P, 0.001]. VsEP thresholds for CochG88E/G88E mice were
significantly higher than for Cochþ/þ mice and the oldest
age groups (17, 19 and 21 months) each had significantly
higher VsEP thresholds than 11-month-old mice (post-hoc
least significant difference, P ¼ 0.015, 0.006 and 0.0001,
respectively). These results suggest that gravity receptor func-
tion declines with advancing age for both genotypes, but
CochG88E/G88E mice have a greater deficit at all ages tested.
Interestingly, VsEP thresholds for the CochG88E/þ mice were
similar to the Cochþ/þ mice at the youngest and oldest ages
tested.
Although gravity receptor (otolithic organs) function for the
CochG88E/G88E mice appeared to be affected as early as 11
months, auditory function at 11 months was identical for all
genotypes (Figs 4 and 5). Distortion product otoacoustic emis-
sion (DPOAE) amplitudes of CochG88E/G88E mice at 19
months were slightly reduced for the mid-frequencies
(5–10 dB smaller) (Fig. 5). One 19-month-old CochG88E/
G88E mouse had much higher ABR thresholds than the other
CochG88E/G88E mice (data not shown) and had essentially
absent DPOAEs indicating that it was more substantially
affected with hearing loss. This mouse also had absent
VsEPs, indicating concomitantly more severe phenotypes in
both the hearing and gravity receptor systems. By 21 months
of age, DPOAE amplitudes for the CochG88E/G88E mice were
Figure 2. Immunohistochemistry on postnatal (3-month-old) CochG88E/G88E
(C, G) and Cochþ/þ (A, E) mouse cochlea (A, C 150) and crista of the pos-
terior ampulla in the vestibular system (E, G 200) with anti-cochlin. Immuno-
staining (in the left panels) appears as a reddish brown DAB reaction product; no
counterstain was applied on these sections. Serial sections stained with H&E are
shown in parallel in the right panels. The CochG88E/G88E mice contain only
mutant Coch, therefore all immunostaining represents mutant cochlin, confirm-
ing successful translation of the mutant cochlin protein. The pattern of
immunostaining in the CochG88E/G88E inner ear is similar to that of the
Cochþ/þ mice, as previously described (4). Prominent cochlin immunostaining
is present in the fibrocytes and in the extracellular matrix throughout the
spiral ligament [filled arrows in (A)] and spiral limbus [open arrow in (A)]
and in the fibrocytes and stroma underlying the sensory epithelium in
the crista [open arrow in (E)], as well as in the ampullary wall [filled arrow
in (E)].
Figure 3. Means and standard errors for VsEP thresholds as a function of age.
Cochþ/þ and CochG88E/G88E mice are represented at all ages tested. CochG88E/þ
mice were tested at the youngest and oldest ages. Although age-related decline in
gravity receptor sensitivity can be seen for all genotypes, VsEP thresholds for
CochG88E/G88E mice were significantly higher than for Cochþ/þ mice at all
ages tested, indicating poorer vestibular function for CochG88E/G88E mice. In
fact, at 19 and 21 months of age, two of the CochG88E/G88E mice had no measur-
able VsEP.
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substantially smaller than for Cochþ/þ mice (up to 30 dB
smaller) and ABR thresholds were substantially higher than
for wild-types. Indeed, six of the eight CochG88E/G88E mice
tested at 21 months had absent DPOAEs and absent ABRs
at the maximum stimulus levels of 32 and 41 kHz frequencies,
and four of eight CochG88E/G88E mice tested had absent ABRs
at all frequencies; therefore, the ABR mean thresholds shown
in Figure 4 likely underestimate actual auditory thresholds.
CochG88E/þ mice at 21 months showed elevated ABR
thresholds at the same level as the CochG88E/G88E mice. The
CochG88E/þ mice also displayed reduced DPOAE amplitudes.
Overall, the functional results suggest that vestibular and
cochlear dysfunction occur in the DFNA9 mouse model, but
not simultaneously. Vestibular function, particularly gravity
receptor function, is affected beginning as young as
11 months when cochlear function appears to be normal. Ves-
tibular deficit increases with advancing age, including pro-
found deficits identified in two elderly CochG88E/G88E mice.
Cochlear function begins to deteriorate at advanced ages.
Since few studies have systematically evaluated vestibular
function in patients with DFNA9, the extent of vestibular dys-
function and age of onset are not well characterized. However,
some clinical reports of DFNA9 patients do indicate onset of
vestibular malfunction to precede hearing loss, similar to the
situation observed in this mouse model. Studies on a Dutch
family bearing this mutation revealed start of hearing deterio-
ration at age 46–49 and onward, and onset of vestibular dys-
function at 46 years of age (15). Similarly, a large study of
Figure 4. Means and standard errors for ABR thresholds at 8, 16, 32 and 41.2 kHz. Data for all genotypes at two ages are shown. At 21 months, four of eight
CochG88E/G88E mice had absent ABRs at all frequencies tested, and two of three CochG88E/þ mice had absent ABRs in three of four frequencies tested; therefore,
symbols for these groups represent a conservative estimate of ‘average’ thresholds. Arrows denote that true thresholds may be higher than estimated. Overall, the
data demonstrate an age-related decline in hearing among all genotypes, but the most substantial declines were seen in the CochG88E/G88E mice where half of the
animals tested had profound hearing loss at all frequencies. CochG88E/þ mice also show decline in auditory function at a level similar to that of the CochG88E/G88E
mice.
Figure 5. Average DPOAE amplitudes are shown at 19 and 21 months. Error bars represent standard errors. Primaries (f2/f1 ¼ 1.25) from 5 to 55 kHz were
presented at 65 dB SPL. At 19 months, DPOAEs were present for CochG88E/G88E and Cochþ/þ mice although emissions for CochG88E/G88E mice were
10–15 dB smaller than those of the Cochþ/þ mice. At 21 months, smaller DPOAE amplitudes were recorded for all genotypes suggesting age-related
changes; however, emissions for the CochG88E/G88E mice decreased by up to 20 dB while Cochþ/þ mice emissions dropped only by 10 dB. Emission ampli-
tudes for CochG88E/G88E mice were substantially smaller than those of Cochþ/þ mice at 21 months. Consistent with the ABR results, half of the CochG88E/G88E
mice (i.e. those with absent ABRs) also had absent DPOAEs (i.e. DPOAE amplitudes indistinguishable from the noise floor).
Human Molecular Genetics, 2008, Vol. 17, No. 21 3429
74 individuals in the Netherlands bearing the P51S mutation,
in the same domain of cochlin as the G88E mutation, also
showed the onset of vestibular malfunction (34 years of age)
to precede onset of hearing deterioration (43 years of age,
onwards) (17). Another study of DFNA9 patients, with the
C542F mutation (9), demonstrates that VEMPs (vestibular-
evoked myogenic potentials) were absent in two of three
DFNA9 patients tested, indicating saccular otolithic deficits.
These results are in agreement with our mouse VsEP results,
which also demonstrate otolithic deficits. In this study (9),
canal dysfunctions in some subjects [bilateral weakness for
calorics and reduced VOR (vestibular ocular reflex) gains in
rotary chair testing] were implicated. We cannot rule out
canal dysfunction in the mouse model at this time, as VOR
testing has not been performed.
Onset of hearing loss in patients with DFNA9 is quite late,
up to the fifth decade. Late-onset hearing loss in this mouse
model is consistent with findings reported in human patients.
Earlier onset of vestibular malfunction in this mouse model,
as well as the human VOR data (15,17), strongly indicate
that vestibular testing, including measures that evaluate
ampullar and macular end organs, should be considered in
the clinical evaluation of patients with DFNA9.
Histopathology
Initial examination of CochG88E/G88E mice at 1 year of age
revealed some deterioration of type IV fibrocytes of the spiral
ligament seen as loss of nuclei (data not shown). However, at
more advanced ages, the loss of type IV fibrocytes observed in
the CochG88E/G88E were similar to changes seen in the
Cochþ/þ mice. In CochG88E/G88E mice of 21 (n ¼ 8) and 26
(n ¼ 2) months of age, histology did not reveal obvious deterio-
ration of cochlear and vestibular sensory epithelia (Fig. 6). Inter-
estingly, however, CochG88E/G88E mice at this age have
pronounced hearing and vestibular symptoms.
In addition, our mouse model did not show the eosinophilic
deposits characteristic of DFNA9 suggesting that there is no
detectable cochlin aggregation in the mouse at the ages
tested. It is possible that these microfibrillar deposits have
not yet formed to the degree of visibility and are at a lower
level than detectable at the time of analysis in the mouse. It
is also possible that the histopathology in the moue exhibits
different expressivity from that in the human where eosino-
philic deposits are observed in end-stage DFNA9.
MATERIALS AND METHODS
Construction of the targeting vector
To construct a mutant Coch targeting vector (Fig. 7A), we
screened a mouse 129 genomic library in EMBL3 phage
(gift of Dr R. Maas, Boston, MA, USA) (18), using radio-
labeled Coch cDNA probes by standard methods. Coch
genomic clones were isolated and characterized by restriction
mapping. A 5.58 kb fragment spanning introns 3 to 8 of Coch
was subcloned into pBluescript II SK vector (Stratagene, La
Jolla, CA, USA). A nucleotide change in exon 5 (A to G),
translating into the p.G88E mutation was introduced
using QuikChange site-directed mutagenesis following the
manufacturer’s protocol (Stratagene). A unique AvrII site
was introduced into intron 5 by the same method, to allow sub-
sequent cloning of a neomycin-resistant gene, pgk-neo,
flanked by loxP sites, for positive selection of embryonic
stem (ES) cells transfected with the construct. The 5.58 kb
Coch genomic fragment containing the mutation was cloned
into a vector containing the thymidine kinase (tk) gene for
negative selection (gift of Dr R. DePinho, Boston, MA,
USA), with the tk gene positioned upstream of the 50 end of
the Coch fragment. A 2 kb loxP–neo–loxP cassette was
then cloned into intron 5. The resulting targeting vector
(Fig. 7A) has a shorter homologous recombinant arm of
1.68 kb derived from the 50 end of the Coch fragment,
upstream of the neo cassette, and a longer homologous recom-
binant arm of 3.9 kb from the 30 side of the Coch fragment,
downstream of neo.
Figure 6. Photomicrograph of (A) the cochlear duct of a 26-month-old
CochG88E/G88E mouse, and (B) the utricular macula and (C) saccular macula
of a 21-month-old CochG88E/G88E mouse. Some loss of type IV fibrocytes in
the cochlea in these mice is observed, but similar changes are present in the
Cochþ/þ mice (data not shown). There is no obvious deterioration of cochlear
and vestibular sensory epithelia.
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Generation of CochG88E/G88E mutant mice
The targeting construct was linearized with a unique AscI site,
30 of the Coch construct and electroporated into J1
(129-derived) ES cells. Homologous recombinants were
identified by both PCR and Southern blot analysis. For PCR
analysis (Fig. 7A), a forward primer upstream of the 50 Coch
homology arm in the targeting construct (50-GTG CTG CCT
TCC ATA TTC CTT TGG-30) and a reverse primer in neo
(50-CGC ATT GTT AGA TTT CAT ACA CGG-30) were
used, yielding a 2.26 kb fragment. For the long homologous
arm, a forward primer in neo (5-0TAT ACG AAG TTA TTA
GGT CCA GCG-30) and a reverse primer in the 30 region
external to the homologous arm of the targeting construct
(50-CAT GTA AAG AGA GCT AGT GTG ATG-30) were
used, yielding a 4.2 kb fragment. The amplified products
were sequenced to confirm homologous recombination of the
construct into the genomic Coch targeted locus, as well as
presence of the targeted mutation and accuracy of all exons,
exon–intron junctions and neo sequence.
Southern blot analysis (Fig. 7B) using probes external to the
genomic DNA in the targeting vector was performed for both
the 50 and 30 sides of the homologous regions. Southern blots
of BamHI and HindIII digests of the ES cell genomic DNA
probed with a 50 probe yielded 4.57 and 7.8 kb band, respect-
ively, in the wild-type, and a 3.77 and 6.45 kb band, respect-
ively, in the targeted allele. BglII and PstI genomic digests
probed with a 30 probe yielded 9.16 and 7.5 kb bands, respect-
ively, in the wild-type, and 11.2 and 5.0 kb bands, respect-
ively, in the targeted allele.
Two rounds of transfections of the mutant Coch targeting
construct into J1 ES cells were performed, yielding 240
ES cell clones, which were screened for homologous recombi-
nation. A total of four ES cell clones were found to be hom-
ologous recombinants. Integrity of all exons, the introduced
mutation, loxP sites, and accurate recombination of homolo-
gous arms were screened by PCR, Southern blots and sequen-
cing. One homologous recombinant clone had a small
insertion from the vector at the end of one homologous arm,
Figure 7. (A) Representation of the Coch targeting construct, homologous recombination with the wild-type allele (targeted locus), screening strategy for recom-
binants by PCR analysis, and removal of the neo cassette in the targeted allele, followed by PCR analysis to identify recombinants with neo excised.
(B) Screening strategy for homologous recombinants by Southern blot analysis.
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and another had not incorporated the mutant base pair; there-
fore these clones were not used for blastocyst injections. The
third clone, which appeared not to have any aberrations in
homologous recombination, yielded very few chimera, none
of which showed germline transmission of the mutant allele.
Subsequently this ES cell clone was karyotyped and shown
to be mosaic for trisomy 8, which may have been the cause
of unsuccessful germline transmission. The fourth ES cell
clone showed homologous recombination and no other
defects as verified further by sequencing of the mutation,
exons and borders of the homologous arms. This ES cell
clone was used for microinjection into C57/6 blastocysts,
which were implanted into pseudopregnant mice and resulted
in several chimera which showed germline transmission of the
Coch G88E allele.
Male chimeric mice with high levels of ES cell contribution
were backcrossed to C57BL/6 females. F1 heterozygous off-
spring with agouti coat color were further tested by genotyping
using tail DNA for PCR and Southern blot analysis to confirm
germline transmission of the mutant Coch construct. For PCR
analysis of F1 genotyping, we employed a forward primer in
exon 5 (50-TTC CTG GTC GAG AGA ACT AC-30) and two
reverse primers, one in neo (50-CGC ATT GTT AGA TTT
CAT ACA CGG-30) and the other in exon 6 (50-CTT CCT
GGG TAC TGC TTT TGC-30), yielding a 400 and a 550 bp
amplified product in the targeted and wild-type alleles,
respectively.
The neo cassette flanked by loxP sites was then excised from
the targeted locus by breeding F1 heterozygotes with a transgenic
mouse carrying EIIa-cre (19), leaving a loxP site in intron 5 of
Coch (Fig. 7A). Deletion of the neo gene in the F1 offspring
was assayed by PCR of tail DNA using forward and reverse
primers (50-TCAACCATGGGACA GAGTTACC-30 and
50-TTGATGTATTTGAAAAGCAC-30) flanking the remaining
loxP site, yielding a 276 and a 176 bp amplified product in the
targeted and the wild-type alleles, respectively (Fig. 7A). Hetero-
zygotes with excised neo were then crossed with the CBA/CaJ
strain, and those with germline transmission of the excised neo
and loss of the cre transgene were identified. Breeding to the
CBA/CaJ strain for at least 10 generations was continued,
because this strain does not exhibit significant hearing loss at
advanced ages, and therefore does not confound hearing analysis
of the mutant mouse at advanced ages. Intercrosses from the first
and third generations of CBA/CaJ crosses were performed to
generate cohorts of mice with all three genotypes for functional
and histological analyses.
Tissues
Mouse tissues were obtained according to guidelines and
protocols approved by the Harvard Medical School Standing
Committee on Animals (Boston, MA, USA). For RNA iso-
lation, spleen tissue was dissected from a CochG88E/þ mouse
and processed as described in the following section. For
histology and immunohistochemistry, mice were perfused
intracardially and tissues fixed in 4% paraformaldehyde.
After removal of the stapes from the oval window, and pier-
cing of the round window, 4% paraformaldehyde fixative
was perfused gently through the cochlea. Inner ears were
immersed in fixative for 24 h, followed by decalcification in
120 mM ethylenediaminetetraacetic acid (EDTA) for 1 week
at room temperature, and embedded in paraffin by standard
histologic procedures. Serial sections were obtained at
5–8 microns thickness and used for staining with hematoxylin
and eosin (H&E) and for immunohistochemistry.
Also for histologic evaluation, osmium tetroxide staining and
embedding in Araldite resins (Polysciences, Warrenton, PA,
USA) was performed, as this technique yields better mor-
phology of tissues. Mice were perfused intracardially with
2.5% glutaraldehyde and 1.5% paraformaldehyde in a 65 mM
phosphate buffer. Both petrous temporal bones were extracted
and the round and oval windows were opened to allow intrala-
byrinthine perfusion of fixative. After overnight postfixation
in the same fixative at room temperature, cochleas were osmi-
cated (1% OsO4 in dH2O) for 1 h and decalcified (100 mM
EDTA with 0.4% glutaraldehyde) for 3 days. After decalcifica-
tion, cochleas were dehydrated in ethanols and propylene oxide
and then embedded in Araldite resins and sectioned at 40 mM
with a carbide steel knife. A total of 10 CochG88E/G88E mice
(eight at 21 months old, and two at 26 months old), and seven
Cochþ/þ mice (five at 21 months old, and two at 26 months
old) were analyzed for histology.
RNA isolation and RT–PCR
Total cellular RNAs were isolated (20) from a CochG88E/þ
mouse spleen and reverse transcribed using SuperScript III
(Invitrogen, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. PCR of the cDNA was performed for 30
cycles under standard conditions, with a 538C annealing,
using forward (50-TCC ACG GAG ATC CTC GCC ATG-30)
and reverse (50-TGC ACG TAT TCC TTG AGT TGT
CAG-30) primers in exons 2 and 12, respectively. The ampli-
fied product was gel isolated and sequenced.
Immunohistochemistry
Immunostaining was performed using an anti-cochlin antibody
generated against a peptide in the vWFA1 domain of cochlin
(Fig. 1), corresponding to amino acid residues 163–181 of
human cochlin, identical to the residues in murine and bovine
cochlin (21). Anti-serum was purified through a protein A
sepharose column, followed by peptide-affinity chromato-
graphy. This antibody (anti-cochlin/vWFA1 domain) recog-
nizes all three different-sized isoforms of cochlin.
Immunohistochemistry was performed as previously
described (4). Briefly, paraffin-embedded sections from post-
natal CochG88E/G88E and Cochþ/þ mice, were incubated with
anti-cochlin/vWFA1 domain antibody overnight at room temp-
erature, washed, and incubated with a secondary biotinylated
anti-rabbit IgG (Vector Labs, Burlingame, CA, USA). Immuno-
staining was visualized by incubation with the Vectastain ABC
reagent (Vector Labs) followed by 3,30-diaminobenzidine
(DAB). Sections were not counterstained.
VsEP, ABR and DPOAE measurements
Animals and animal preparation. The use of animals for these
studies was approved by the Institutional Animal Care and Use
Committee at East Carolina University. Homozygous,
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CochG88E/G88E (n ¼ 17), heterozygous, CochG88E/þ (n ¼ 14)
and Cochþ/þ wild-type littermates (n ¼ 15) were studied at
five ages: 11, 13, 17, 19 and 21 months. Mice were anesthe-
tized with a ketamine (18 mg/ml) and xylazine (2 mg/ml)
solution (5–7 ml per gram body weight injected intraperitone-
ally). Core body temperature was maintained at 37.0+ 0.18C
using a homeothermic heating blanket system (FHC, Inc.,
Bowdoin, ME, USA). VsEPs were measured at all ages,
auditory brainstem responses (ABRs) are reported at 11 and
21 months of age, and DPOAEs were measured at 19 and
21 months only. Six animals were measured at two or more
ages.
Vestibular stimulus and stimulus coupling. VsEP recordings
were based on methods for mice published by Jones and
Jones (22) and Jones et al. (23–25), and are briefly described
later. The published methods were modified to utilize a non-
invasive coupling system for securing the head to the mechan-
ical shaker. Linear acceleration pulses, 2 ms duration, were
presented to the cranium in the naso-occipital axis using two
stimulus polarities, normal (þGx axis) and inverted (2Gx
axis). Stimuli were presented at a rate of 17 pulses/s. Stimulus
amplitude ranged from þ6 to –18 dB re: 1.0 g/ms (where
1 g ¼ 9.8 m/s2) adjusted in 3 dB steps.
Stimuli were delivered to the head using a voltage-
controlled mechanical shaker. The head was coupled to a
custom platform with a custom head clip, a lightweight
plastic spring clip with tines modified to encircle the head
anterior to the pinnae. The spring clip was screwed to the
custom platform mounted to the mechanical shaker. Although
previously published reports using VsEPs utilized an invasive
surgical approach to couple the cranium to the shaker, the
coupling used here was non-invasive.
ABR stimulus and stimulus coupling. For ABR testing, tone
burst stimuli were generated by a signal generator (Agilent
HP 23201A or Stanford Research Systems SRS785 signal ana-
lyzer) and controlled using custom software and Tucker Davis
Technologies (TDT, Gainesville, FL, USA) modules (TG6,
SW2, PA4). Tone bursts at 8, 16, 32 and 41.2 kHz had
1.0 ms rise–fall times with 1.0 ms plateau (3 ms total dur-
ation). Stimuli for ABR testing were calibrated using a
Bruel & Kjaar 1/4 in. microphone and Nexus amplifier.
Stimuli were calibrated in dB peSPL and were presented via
high frequency transducers (TDT ED1 driver, EC1 speakers)
coupled at the left ear via PE tubing. Auditory stimuli were
presented at a rate of 17 stimuli/s.
VsEP and ABR recording parameters. Stainless steel wire was
placed subcutaneously at the nuchal crest to serve as the non-
inverting electrode. Needle electrodes were placed posterior to
the left pinnae and at the ventral neck for inverting and ground
electrodes, respectively. Traditional signal averaging was used
to resolve responses in electrophysiological recordings.
Ongoing electroencephalographic activity was amplified
(200 000), filtered (300 to 3000 Hz, 26 dB amplitude
points) and digitized (1024 points, 10 ms/pt). Two hundred
and fifty six primary responses were averaged for each
VsEP or ABR response waveform. All responses were
replicated. VsEP recordings began at the maximum stimulus
intensity (i.e. þ6 dB re: 1.0 g/ms) with and without acoustic
masking, then intensity was dropped to 218 dB and raised
in 3 dB steps to complete an intensity profile. A broad band
forward masker (50–50 000 Hz, 97 dB SPL) was presented
during VsEP measurements to verify absence of cochlear
responses (22). ABR intensity series was collected with a des-
cending series of stimulus intensities (12 dB steps) beginning
at 100 dB peSPL.
DPOAE stimulus and recording. Methods for recording
DPOAEs were similar to those previously described (26,27).
Stimuli for DPOAEs were generated and controlled with
modules from TDT. Pure tone frequencies (f1, f2, f2/f1
ratio ¼ 1.25), at equal levels (L1 ¼ L2 ¼ 60 dB SPL),
150 ms duration, were generated with independent sources
(Agilent HP 23201A signal generators) and routed through
separate drivers to mix acoustically in the ear canal (via
plastic tubing placed securely at the external acoustic
meatus). Stimuli were calibrated in a 0.1 ml coupler, which
simulated the mouse ear canal volume. Stimulus frequencies
for the primaries were such that geometric mean [GM ¼
(f1  f2)0.5] frequencies ranged from 6.0 to 48.5 kHz (at
least eight frequencies per octave). Ear canal sound pressure
levels were recorded with a low noise probe microphone (Ety-
motic ER 10Bþ). The microphone output was amplified and
routed to a dynamic signal analyzer (Stanford Research
Systems SRS785) for sampling (at 200 kHz) and fast Fourier
transform (FFT). The amplitude of f1, f2, and the 2f1–f2 dis-
tortion product were measured from the FFT waveform. The
noise floor was measured from the amplitudes in the five fre-
quency bins above and below the 2f1–f2 component. The
recording system was also tested periodically in the 0.1 ml
coupler to assess the presence of artifact distortion products.
Frequencies where distortion products were present in the
test cavity were excluded from further analyses; however no
artifactual distortion was identified.
Data analysis. The first three positive and negative response
peaks were scored for VsEPs. Response peak latencies
(measured in milliseconds, ms), peak to peak amplitudes
(measured in microvolts, mV) and thresholds (measured in
dB re: 1.0 g/ms) were quantified for VsEPs. Threshold (in
dB peSPL) were obtained for ABR waveforms and amplitudes
were quantified for DPOAEs. Descriptive statistics were cal-
culated for each measure of each genotype. Animals with
absent-evoked potentials contributed to an estimated mean
of the group by replacing the ‘no response’ data points with
the maximum possible stimulus level (þ9 dB for VsEP and
100 dB peSPL for ABR). All DPOAE amplitudes contributed
to the DPOAE mean data.
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